Piperlongumine loaded PLGA nanoparticles inhibit cancer stem-like cells through modulation of STAT3 in mammosphere model of triple negative breast cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Piperlongumine loaded PLGA nanoparticles inhibit cancer stem-like cells through modulation of STAT3 in mammosphere model of triple negative breast cancer
Authors
Keywords
Triple negative breast cancer, Cancer stem cells, Piperlongumine, Nanomedicine, STAT3
Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 616, Issue -, Pages 121526
Publisher
Elsevier BV
Online
2022-01-30
DOI
10.1016/j.ijpharm.2022.121526
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A new sesquiterpenoid from the shoots of Iranian Daphne mucronata Royle with selective inhibition of STAT3 and Smad3/4 cancer-related signaling pathways
- (2020) Mustafa Ghanadian et al. DARU-Journal of Pharmaceutical Sciences
- Influence of Formulation Parameters on Redispersibility of Naproxen Nanoparticles from Granules Produced in a Fluidized Bed Process
- (2020) Martin Wewers et al. Pharmaceutics
- Phytonanomedicine: a novel avenue to treat recurrent cancer by targeting cancer stem cells
- (2020) Priyanka Mohapatra et al. DRUG DISCOVERY TODAY
- Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- (2020) Surya Kant Tripathi et al. PHARMACOLOGICAL RESEARCH
- Phytochemical Targeting of STAT3 Orchestrated Lipid Metabolism in Therapy-Resistant Cancers
- (2020) Carmen Tse et al. Biomolecules
- STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population
- (2020) Giacomo Canesin et al. Scientific Reports
- Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance
- (2020) Po-Chang Shih et al. DRUG DISCOVERY TODAY
- Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy
- (2019) Jiabei He et al. Cell Death & Disease
- STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
- (2019) Jiang-Jiang Qin et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice
- (2019) Stephanie Saw et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
- (2019) Park et al. Cancers
- Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress
- (2019) Qianqian Zhang et al. Frontiers in Pharmacology
- Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities
- (2019) De Angelis et al. Cancers
- Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker
- (2018) Christopher J O'Conor et al. Biomarkers in Medicine
- Evaluation of curcumin loaded chitosan/PEG blended PLGA nanoparticles for effective treatment of pancreatic cancer
- (2018) Geetanjali Arya et al. BIOMEDICINE & PHARMACOTHERAPY
- STAT3, stem cells, cancer stem cells and p63
- (2018) Michaela Galoczova et al. CELLULAR & MOLECULAR BIOLOGY LETTERS
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1
- (2018) Wei Hang et al. ONCOGENE
- PDE5 inhibition eliminates cancer stem cells via induction of PKA signaling
- (2018) Saskia Klutzny et al. Cell Death & Disease
- Sphere-Formation Assay: Three-Dimensional in vitro Culturing of Prostate Cancer Stem/Progenitor Sphere-Forming Cells
- (2018) Hisham F. Bahmad et al. Frontiers in Oncology
- Cancer stem cells (CSCs) in cancer progression and therapy
- (2018) Masoud Najafi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer
- (2018) Alexander Ring et al. Cancers
- Enhancement of Aqueous Solubility and Dissolution of Celecoxib through Phosphatidylcholine-Based Dispersion Systems Solidified with Adsorbent Carriers
- (2018) Kanghee Jo et al. Pharmaceutics
- The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer
- (2017) Pingting Zhou et al. Molecular Cancer
- Targeted Delivery of STAT-3 Modulator to Breast Cancer Stem-Like Cells Downregulates a Series of Stemness Genes
- (2017) Santosh K. Misra et al. MOLECULAR CANCER THERAPEUTICS
- Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models
- (2017) Jiyan Mohammad et al. Oncotarget
- Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes
- (2017) Jun Hu et al. Oncotarget
- Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment
- (2017) Pedro M. Aponte et al. Stem Cells International
- Cancer stem cells and epithelial-mesenchymal transition: Novel therapeutic targets for cancer
- (2016) Toshiyuki Ishiwata PATHOLOGY INTERNATIONAL
- Increased cancer stem cell invasion is mediated by myosin IIB and nuclear translocation
- (2016) Dustin Thomas et al. Oncotarget
- Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
- (2015) Andreas Wicki et al. JOURNAL OF CONTROLLED RELEASE
- Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy
- (2015) A Borah et al. Oncogenesis
- Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer
- (2015) Jong-Lyel Roh et al. Oncotarget
- Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells
- (2014) Tae Hyong Kim et al. NEURO-ONCOLOGY
- Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer
- (2014) U Bharadwaj et al. ONCOGENE
- ROS inhibitorN-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors
- (2013) Marianna Halasi et al. BIOCHEMICAL JOURNAL
- Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies
- (2013) Valentina Guarneri et al. DRUGS
- Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model
- (2013) Fahima Dilnawaz et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals
- (2013) Shu Wang et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Synthesis and drug delivery of novel amphiphilic block copolymers containing hydrophobic dehydroabietic moiety
- (2013) Jing Wang et al. Journal of Materials Chemistry B
- Overview of the therapeutic potential of piplartine (piperlongumine)
- (2012) Daniel P. Bezerra et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
- (2011) Lauren L.C. Marotta et al. JOURNAL OF CLINICAL INVESTIGATION
- Coformulation of Doxorubicin and Curcumin in Poly(d,l-lactide-co-glycolide) Nanoparticles Suppresses the Development of Multidrug Resistance in K562 Cells
- (2011) Ranjita Misra et al. MOLECULAR PHARMACEUTICS
- PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
- (2010) Sarbari Acharya et al. ADVANCED DRUG DELIVERY REVIEWS
- Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells
- (2010) Y. Li et al. CLINICAL CANCER RESEARCH
- Therapeutic Nanoparticles for Drug Delivery in Cancer
- (2008) K. Cho et al. CLINICAL CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started